Integrated Filing — IndAS



General information about company

Scrip Code 524280
NSE Symbol KOPRAN
MSEI Symbol NOTLISTED
ISIN INE082A01010
Name of company KOPRAN LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 19-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 19-05-2026   11:30:00
End date and time of board meeting 19-05-2026   14:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 23,401.83 68,142.36
Other income 9.04 34.57
Total income 23,410.87 68,176.93
2 Expenses
(a) Cost of materials consumed 13,992.94 43,118.17
(b) Purchases of stock-in-trade 183.95 373.82
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 477.58 409.56
(d) Employee benefit expense 1,645.57 6,521.31
(e) Finance costs 317.08 1,047.15
(f) Depreciation, depletion and amortisation expense 451.58 1,747.27
(f) Other Expenses
1 Other exepense 3,044.53 9,929.46
2 Foreign Exchange Loss 762.75 1,594.57
Total other expenses 3,807.28 11,524.03
Total expenses 20,875.98 64,741.31
3 Total profit before exceptional items and tax 2,534.89 3,435.62
4 Exceptional items 0.00 0.00
5 Total profit before tax 2,534.89 3,435.62
6 Tax expense
7 Current tax 578.33 903.61
8 Deferred tax 70.01 (41.11)
9 Total tax expenses 648.34 862.50
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,886.55 2,573.12
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,886.55 2,573.12
17 Other comprehensive income net of taxes 104.72 51.85
18 Total Comprehensive Income for the period 1,991.27 2,624.97
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 4,828.56 4,828.56
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 48,199.49
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.91 5.33
Diluted earnings (loss) per share from continuing operations 3.91 5.33
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.91 5.33
Diluted earnings (loss) per share from continuing and discontinued operations 3.91 5.33
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1) The above Statement of consolidated and standalone audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (lndian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in lndia. There is no minority interest. 2) The above Statement of consolidated and standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 19, 2026. The Statutory Auditors do not have any modification/qualification. 3) The Company and the subsidiaries together referred to as Group are engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on Operating Segment Reporting. 4) The Government of India, vide notification dated November 21, 2025, has notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “New Labour Codes”), which consolidate and replace twenty-nine existing central labour laws into unified framework governing employee benefits during employment and post-employment. The New Labour codes, amongst other things introduced changes, including a uniform definition of wages for statutory purposes. Once Central / State Rules are notified by the Government on all aspects of the Codes, the management of the company will evaluate its impact, on the employee benefits and provide for the same in the books of accounts, if necessary. 5) The Board of Directors of Kopran Limited and Kopran Laboratories Limited in their Board Meetings held on 20th March, 2025 and subsequently on 8th August, 2025 have subject to the approval of Stock Exchanges, shareholders, National Company Law Tribunal (NCLT) and other relevant Authorities, proposed and approved a Scheme of Amalgamation ( Merger by absorption) between Kopran Laboratories Limited the Transferor Company and Kopran Limited the Transferee Company and their respective shareholders. The Appointed Date is 1st January, 2025. The Company has received “NO Adverse Observation /observation letter ” for the proposed Scheme of amalgamation from BSE Limited and National Stock Exchange of India Limited (NSE) where the shares of the Company are listed. The Hon’ble National Company Law Tribunal (NCLT) Mumbai Bench, Mumbai vide its Order 9th April, 2026 have admitted the Application and issued various directions including convening the meetings of Equity Shareholders and Creditors. Said meeting as per the NCLT directions will be held on Wednesday the 3rd June, 2026. The effect of the Scheme will be given in the books of accounts only after the Hon’ble NCLT Mumbai Bench sanctions the Scheme of Amalgamation. 6) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 33,704.70
Capital work-in-progress 232.66
Investment property 0.00
Goodwill 0.58
Other intangible assets 939.54
Intangible assets under development 2,246.19
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 5.66
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Others 581.91
2 Other non-current financial assets 807.33
Total of other non-current financial assets 1,389.24
Total non-current financial assets 1,394.90
Deferred tax assets (net) 0.00
Other non-current assets
Total of other non-current assets
Total non-current assets 38,518.57
2 Current assets
Inventories 16,420.78
Current financial asset
Current investments 0.00
Trade receivables, current 26,265.71
Cash and cash equivalents 68.20
Bank balance other than cash and cash equivalents 654.02
Loans, current 814.51
Other current financial assets
Total of other current financial assets 9.33
Total current financial assets 27,811.77
Current tax assets (net) 151.21
Other current assets
1 Other current assets 7,933.91
Total of other current assets 7,933.91
Total current assets 52,317.67
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 90,836.24
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,828.56
Other equity 48,199.49
Total equity attributable to owners of parent 53,028.05
Non controlling interest 0.00
Total equity 53,028.05
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,394.81
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 1,394.81
Provisions, non-current 894.02
Deferred tax liabilities (net) 901.35
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 3,190.18
Current liabilities
Current financial liabilities
Borrowings, current 13,874.44
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 959.04
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 14,822.65
Total Trade payable 15,781.69
Other current financial liabilities
1 Other current financial liabilities 3,967.53
Total of other current financial liabilities 3,967.53
Total current financial liabilities 33,623.66
Other current liabilities 547.15
1 Other current liabilities 547.15
Total of other current liabilities 547.15
Provisions, current 151.80
Current tax liabilities (Net) 295.40
Deferred government grants, Current 0.00
Total current liabilities 34,618.01
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 37,808.19
Total equity and liabilites 90,836.24
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plans 128.66 41.56
Total Amount of items that will not be reclassified to profit and loss 128.66 41.56
2 Income tax relating to items that will not be reclassified to profit or loss 32.38 10.47
3 Amount of items that will be reclassified to profit and loss
1 Exchange difference in translating the financial statement of foreign operation 8.44 20.76
Total Amount of items that will be reclassified to profit and loss 8.44 20.76
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 104.72 51.85



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,435.62
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,047.15
Adjustments for decrease (increase) in inventories 521.54
Adjustments for decrease (increase) in trade receivables, current (4,511.71)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 865.26
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (112.32)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,869.78
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (603.64)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,747.27
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 70.58
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 1,183.76
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (272.25)
Adjustments for dividend income 0.00
Adjustments for interest income 29.88
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 20.31
Other adjustments for non-cash items 18.38
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 3,814.23
Net cash flows from (used in) operations 7,249.85
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 574.78
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 6,675.07
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2.50
Purchase of property, plant and equipment 5,847.73
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 864.78
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets (30.32)
Cash advances and loans made to other parties (189.96)
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 29.88
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (6,459.85)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 664.30
Repayments of borrowings 262.98
Payments of lease liabilities 0.00
Dividends paid 1,448.57
Interest paid 1,047.05
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (2,094.30)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,879.08)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,879.08)
Cash and cash equivalents cash flow statement at beginning of period 1,947.28
Cash and cash equivalents cash flow statement at end of period 68.20





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Khandelwal Jain & Co Yes 31-08-2028